8月19日，莫德納股價在黑色素瘤疫苗3期試驗結果積極的推動下飆升約177%Rothschild & Co以估值過高為由下調MRNA評級，目標價為$81引述“反應過度”— Simon Baker“估值明顯過高”— Simon Baker來源Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. saysCNBCModerna Doubled in a Day. What Happens Now Is the Real Question.MMarketspectator
